Lonza GroupFRA:LO3 -0.07%81 Market Cap is €40,535 Mil as of Jun. 28, 2026. GuruFocus rates FRA:LO3 with a GF Score™ of 81/100 and a GF Value™ of €642.72 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Lonza Group ranks better than 98.17% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lonza Group's share price for the quarter that ended in Dec. 2025 was €576. Lonza Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 70 Mil. Therefore, Lonza Group's market cap for the quarter that ended in Dec. 2025 was €40,230 Mil.
Lonza Group's quarterly market cap
increased
from Dec. 2024 (€20,760 Mil) to Jun. 2025 (€42,621 Mil) but then
declined
from Jun. 2025 (€42,621 Mil) to Dec. 2025 (€40,230 Mil).
Lonza Group's annual market cap
declined
from Dec. 2023 (€21,195 Mil) to Dec. 2024 (€20,760 Mil) but then
increased
from Dec. 2024 (€20,760 Mil) to Dec. 2025 (€40,230 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lonza Group's Enterprise Value for Today is €44,741 Mil.
Lonza Group (FRA:LO3) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lonza Group Market Cap Related Terms
Lonza Group Market Cap Historical Data
* Premium members only.
The historical data trend for Lonza Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lonza Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Lonza Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lonza Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (FRA:LO3) has a Market Cap of €40,535 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lonza Group and its competitors. According to the industry distribution chart, Lonza Group ranks #4 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 1.8%.
Is Lonza Group's Market Cap too high?
Lonza Group's current Market Cap is €40,535 Mil. Based on the distribution chart, Lonza Group ranks #4 out of 218 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Lonza Group has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #4 out of 218 companies for Market Cap. This places Lonza Group in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 55.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 55.55, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 55.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current Market Cap is €40,535 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (FRA:LO3) is currently considered Modestly Undervalued. The stock's GF Value™ is €642.72, compared to a current price of €579.60 — trading 9.8% below its estimated fair value. The current Market Cap is €40,535 Mil. Lonza Group's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lonza Group (FRA:LO3), the current Market Cap is €40,535 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (FRA:LO3) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of €579.60 is trading 9.8% below its estimated GF Value™ of €642.72.
GuruFocus considers Lonza Group to be Modestly Undervalued.
Key valuation signals for FRA:LO3:
Market Cap: €40,535 Mil
GF Value™: €642.72 vs. price of €579.60 (9.8% below fair value)
No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
81GF Score
Get the complete analysis for FRA:LO3
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LO3 has been successfully added to your 
